Case Study: How Pharma Uses NeoGenomics Real-World Oncology Data to Accelerate Biomarker Adoption and Commercial Launch

Biomarker testing is critical for ensuring that cancer patients get the right therapy at the right time. But what happens when new therapies emerge, and their associated biomarkers are not routinely tested for as standard of care?

As the leading oncology diagnostic lab in the US, testing nearly 500,000 cancer patients annually, NeoGenomics is a premier partner for enabling diagnostic market development through its direct-to-provider channels. By harnessing the power of its real-world lab data, NeoGenomics partners with numerous pharmaceutical companies to develop step-by-step precision oncology launch programs designed to drive biomarker awareness.

Learn more about the five tactics that can support your next commercial launch in this NeoEngage case study.



Additional Resources:

The content in the blogs herein relate to the opinions and views expressed by the individual blog author(s) and contributors and are not necessarily the viewpoints held by NeoGenomics Inc., or any of its affiliates or entities.

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients